Spots Global Cancer Trial Database for Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
Official Title: Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma
Study ID: NCT01574729
Conditions
Study Description
Brief Summary: The primary objectives of this study are to investigate the efficacy and safety of surgery combined with rAd-p53 gene therapy in treatment of advanced Non-small-cell lung carcinoma (NSCLC). The study efficacy endpoints include overall survival, progress-free survival, quality of life, and local recurrent rate. The safety endpoint is complications and adverse effects. The study hypothesis: rAd-p53 gene therapy can prolong the overall survival and reduce the local recurrent rate.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
Contact Details
Name: Qunyou Tan, M.D., Ph.D
Affiliation: Institute of Surgery Research, Daping Hospital, Third Military Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
